These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22812568)

  • 21. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience.
    Esposito M; Giunta A; Mazzotta A; Babino G; Talamonti M; Chimenti MS; Chimenti S
    Int J Immunopathol Pharmacol; 2010; 23(2):503-9. PubMed ID: 20646345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
    Gottlieb AB; Langley RG; Strober BE; Papp KA; Klekotka P; Creamer K; Thompson EH; Hooper M; Kricorian G
    Br J Dermatol; 2012 Sep; 167(3):649-57. PubMed ID: 22533447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis].
    Wozel G
    Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intermittent use of etanercept in psoriasis].
    Herrera E; Alcaide AJ
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():18-25. PubMed ID: 20492876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
    Strober BE; Clarke S
    J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment adherence to different etanercept regimens, continuous vs. intermittent, in patients affected by plaque-type psoriasis.
    Esposito M; Gisondi P; Cassano N; Babino G; Cannizzaro MV; Ferrucci G; Chimenti S; Giunta A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S31-4. PubMed ID: 25381971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etanercept therapy allows the tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis.
    Yamauchi PS; Lowe NJ
    Int J Dermatol; 2008 Feb; 47(2):202-4. PubMed ID: 18211500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis.
    Goldsmith DR; Wagstaff AJ
    Am J Clin Dermatol; 2005; 6(2):121-36. PubMed ID: 15799687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
    Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
    J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
    Vender R
    J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
    Mazzotta A; Esposito M; Costanzo A; Chimenti S
    Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Long term efficacy and safety of etanercept in psoriasis].
    García-Patos Briones V; Mollet Sánchez J
    Actas Dermosifiliogr; 2010 May; 101 Suppl 1():12-7. PubMed ID: 20492875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
    Strober BE; Crowley JJ; Yamauchi PS; Olds M; Williams DA
    Br J Dermatol; 2011 Sep; 165(3):661-8. PubMed ID: 21574984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment.
    Gelfand JM; Kimball AB; Mostow EN; Chiou CF; Patel V; Xia HA; Freundlich B; Stevens SR
    Value Health; 2008; 11(3):400-7. PubMed ID: 18489665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
    Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
    Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of etanercept in psoriatic patients previously treated with infliximab.
    Pitarch G; Sánchez-Carazo JL; Mahiques L; Oliver V
    Dermatology; 2008; 216(4):312-6. PubMed ID: 18230978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.